Chronic Obstructive Pulmonary Disease (COPD) and emphysema are debilitating conditions that can make even simple tasks like walking or climbing stairs feel insurmountable. For many in the Texas ...

Approval of First Minimally Invasive Treatment Option in Japan that Helps Patients with Advanced Disease Breathe Easier and Have a Better Quality of Life Over 600,000 Japanese patients suffer from ...

In late March, physicians at the University of Alabama at Birmingham carefully threaded a one-way valve the size of a black-eyed pea into the lower lobe of Dennis Bullock's left lung. Bullock, a ...

The US Food and Drug Administration (FDA) has approved the Zephyr Endobronchial Valve (Pulmonx Corp) to treat breathing difficulty associated with severe emphysema. "Treatment options are limited for ...

Rick Scroggins has worked hard and played hard throughout his 75 years. So, it didn't sit well with him when severe emphysema and chronic obstructive pulmonary disease (COPD) forced him to slow down ...

(Philadelphia, PA) - Temple University Hospital has become the first U.S. center to perform bronchoscopic lung volume reduction using implantation of the Zephyr® Endobronchial Valve (Zephyr® EBV®) to ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation announced today that the French Health Ministry has granted national reimbursement for the Zephyr Endobronchial Valve, the first ...

(NAPSI)—Chronic obstructive pulmonary disease (COPD) affects approximately 16 million Americans and can make even simple daily activities feel overwhelming. For people with severe COPD, walking across ...

Pulmonx ® Corp. announced today that the U.S. Food and Drug Administration (FDA) has approved the Zephyr ® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the ...

CHILLICOTHE— A new, minimally invasive procedure now being offered by Adena Health System for patients suffering from emphysema and COPD. “We’ve actually been talking about doing this type of ...

REDWOOD CITY, Calif. & TOKYO--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the ...